SP
BravenNow
Novonesis edges lower after Q4 results, 2026 outlook trail expectations
| USA | economy | ✓ Verified - investing.com

Novonesis edges lower after Q4 results, 2026 outlook trail expectations

#Novonesis #Q4 results #Organic growth #EBITDA #Market expectations #Biotech #Share price #2026 outlook

📌 Key Takeaways

  • Novonesis shares declined over 1% after Q4 results missed expectations
  • Fourth-quarter sales were €997 million, below the €1.02 billion consensus
  • Planetary Health Biosolutions division underperformed with only 2% organic growth
  • 2026 outlook guided to 5-7% organic growth, below the 6.5% consensus

📖 Full Retelling

Danish biotech group Novonesis (CSE: NSISb) saw its shares decline more than 1% on Wednesday, February 25, 2026, after reporting fourth-quarter results that fell short of market expectations and issuing a 2026 outlook slightly below forecasts. Novonesis reported fourth-quarter sales of €997 million, missing the €1.02 billion consensus estimate according to Jefferies. The company's organic sales growth reached 4%, about 120 basis points below consensus. Adjusted EBITDA came in at €365 million, down 3% versus consensus, with a margin of 36.6%, slightly below expectations. The shortfall was primarily driven by weakness in Planetary Health Biosolutions, where sales rose just 2% organically compared to expectations of roughly 5% growth. Within this division, Agriculture, Energy & Tech performed particularly poorly, showing flat organic growth against consensus expectations for a mid-single-digit increase. In contrast, Food & Health Biosolutions delivered a stronger performance, with segment sales of €446 million slightly ahead of consensus and organic growth of 7% supported by volume and pricing gains. The company's free cash flow before acquisitions reached €102 million in the quarter, up from €91 million a year earlier, while net debt to EBITDA stood at 1.9x. Looking ahead, Novonesis guided for 2026 organic growth of 5-7%, below the 6.5% consensus forecast at the midpoint. It expects adjusted EBITDA margin of 37-38%, around the 37.5% consensus level, implying EBITDA of approximately €1.60-1.68 billion at the midpoint. Jefferies analysts led by Chris Counihan indicated they 'expect slight share price pressure' following the results.

🏷️ Themes

Corporate Earnings, Biotechnology, Market Performance

📚 Related People & Topics

Earnings before interest, taxes, depreciation and amortization

Accounting measure of a company's profitability

Earnings before interest, taxes, depreciation, and amortization, commonly known as EBITDA ( EE-bit-dah, EB-it-dah), is a measure of a company's profitability of the operating business only, thus before any effects of indebtedness, state-mandated payments, and costs required to maintain its asset bas...

View Profile → Wikipedia ↗
Biotechnology

Biotechnology

Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...

View Profile → Wikipedia ↗

Organic growth

Business growth based on output and customer increases

Organic business growth is related to the growth of natural systems and organisms, societies and economies, as a dynamic organizational process, i.e. it relates to business expansion founded on increased output, customer base expansion, and new product development, as opposed to growth by mergers an...

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Earnings before interest, taxes, depreciation and amortization:

🏢 Share repurchase 3 shared
🌐 Free cash flow 3 shared
🏢 Dividend 3 shared
🌐 Renewable energy 3 shared
🌐 Substance (chemistry) 2 shared
View full profile
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices rise 1% as tariff jitters aid haven demand; silver, platinum rally AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address (South Africa Philippines Nigeria) Novonesis edges lower after Q4 results, 2026 outlook trail expectations By Vahid Karaahmetovic Author Vahid Karaahmetovic Earnings Published 02/25/2026, 03:37 AM Novonesis edges lower after Q4 results, 2026 outlook trail expectations 0 NSISb 0.88% Investing.com -- Novonesis (CSE: NSISb ) shares slid more than 1% on Wednesday after the Danish biotech group reported fourth-quarter results that came in below market expectations and issued a 2026 outlook slightly under forecasts. Dive deeper into market-moving corporate earnings with InvestingPro Fourth-quarter sales were €997 million, missing the €1.02 billion consensus estimate cited by Jefferies. Organic sales growth was 4%, about 120 basis points below consensus, the broker said. Adjusted EBITDA came in at €365 million, down 3% versus consensus, with margin at 36.6%, slightly below expectations. The shortfall was driven largely by weakness in Planetary Health Biosolutions, where sales rose just 2% organically versus expectations for roughly 5% growth. Within the division, Agriculture, Energy & Tech was particularly soft, with flat organic growth compared with consensus expectations for a mid-single-digit increase. By contrast, Food & Health Biosolutions delivered a stronger performance. Segment sales were €446 million, slightly ahead of consensus, with organic growth of 7% supported by volume and pricing gains. Free cash flow before acquisitions reached €102 million in the quarter, up from €91 million a year earlier, while net debt to EBITDA stood at 1.9x. Looking ahead, the company guided to 2026 organic growth of 5–7%, below the 6.5% consensus forecast at...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine